The content on this site is intended for healthcare professionals only

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Videos [915]

Latest developments in mHSPC

Prof Kurt Miller and Prof Laura-Maria Krabbe

Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )

Evaluating a polygenic hazard score to predict risk of developing metastatic or ...

Dr Meghana Pagadala - University of California San Diego, San Diego, USA

Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer ( Dr Meghana Pagadala - University of California San Diego, San Diego, USA )

ASCO GU 2022: The latest in CRPC, including PARP combo data

Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Mers...

ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma o...

Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Nether...

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis ( Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in a...

Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spai...

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant th...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO GU 2022: What to watch out for in renal

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2022: What to watch out for in renal ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Maintenance PARP inhibition following chemotherapy for metastatic urothelial car...

Dr Simon Crabb - University of Southampton, Southampton, UK

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma ( Dr Simon Crabb - University of Southampton, Southampton, UK )

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients...

Prof Alfredo Berruti - University Of Brescia, Brescia, Italy

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. ( Prof Alfredo Berruti - University Of Brescia, Brescia, Italy )

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladde...

Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology

Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBri...

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology ( Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBride, Dr Ravindran Kanesvaran & Dr Nicolo Battisti )

More from ecancer